SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

16 May 2024 Evaluate
The total revenue for the quarter ended March 2024 remained nearly unchanged at Rs. 4454.90 millions.The company has announced a 48.05% increase in its profits to Rs . 375.60  millions for the  quarter ended March 2024 compared to Rs. 253.70 millions in the corresponding quarter in the previous year.A decline of 614.10 millions was observed in the OP in the quarter ended March 2024 from 646.60 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 4454.90 4274.60 4.22 17908.10 16666.90 7.45 17908.10 16666.90 7.45
Other Income 40.50 4.90 726.53 85.10 23.30 265.24 85.10 23.30 265.24
PBIDT 614.10 646.60 -5.03 2664.90 2872.20 -7.22 2664.90 2872.20 -7.22
Interest 109.10 86.40 26.27 368.20 250.30 47.10 368.20 250.30 47.10
PBDT 702.30 560.20 25.37 2412.00 2621.90 -8.01 2412.00 2621.90 -8.01
Depreciation 237.30 176.90 34.14 879.80 706.00 24.62 879.80 706.00 24.62
PBT 465.00 383.30 21.31 1532.20 1915.90 -20.03 1532.20 1915.90 -20.03
TAX 89.40 129.60 -31.02 365.80 502.30 -27.17 365.80 502.30 -27.17
Deferred Tax -15.20 6.10 -349.18 38.10 -49.70 -176.66 38.10 -49.70 -176.66
PAT 375.60 253.70 48.05 1166.40 1413.60 -17.49 1166.40 1413.60 -17.49
Equity 184.40 184.30 0.05 184.40 184.30 0.05 184.40 184.30 0.05
PBIDTM(%) 13.78 15.13 -8.87 14.88 17.23 -13.65 14.88 17.23 -13.65

Indoco Remedies Share Price

220.00 2.75 (1.27%)
17-Apr-2026 14:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.90
Dr. Reddys Lab 1229.80
Cipla 1236.25
Zydus Lifesciences 944.20
Lupin 2313.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×